ExploreOutcomeanxiety impact and family burden
Outcome

anxiety impact and family burden

Also known as: Parent-reported anxiety impact (CAIS) and family burden (BAS)
3 findings 1 paper 4 related entities View in graph →

Related entities

interventions
conditions
populations
studys

Findings (27)

None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-
None
improvement

Combination treatment and sertraline were superior to placebo at week 12 on parent-reported anxiety impact and family burden, while CBT was not superior to placebo on anxiety impact but was on family

Effect: improvement; CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-10.3, t=-5.3; SRT b=-7.1, t=-3.5

Size: CAIS: COMB b=-7.7, t=-5.2; SRT b=-6.1, t=-4.0. BAS: COMB b=-

Papers (1)